Program
resmetirom
Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.
Drug pageResmetirom: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Madrigal Pharmaceuticalsits history only | 207 open or running | phase 4since Aug 25, 2026 | Jun 2, 2011 | Dec 2026phase 3 · NCT05500222 |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Nov 18, 2025 | Nov 18, 2025 | none ahead |
| Sagimet Biosciencesits history only | 10 open or running | phase 1since Oct 8, 2025 | Oct 8, 2025 | none ahead |
Also a collaborator on its studies: Celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Jun 2, 2011.
- Jan 22, 2018Phase 1 study in HealthyMadrigal Pharmaceuticals · NCT03413124 · 16 enrolled · United States
- Jun 9, 2018Named resmetiromINNProposed as its International Nonproprietary Name in WHO's List 119 · before, MGL-3196, VIA-3196
- Mar 26, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT03900429 · 1,759 enrolled · United States, Australia, Austria and more
- Dec 11, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04197479 · 1,343 enrolled · United States, Puerto Rico
- Oct 22, 2020Phase 1 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04643795 · 87 enrolled · United States
- Dec 10, 20202 phase 1 studies in HealthyMadrigal Pharmaceuticals · NCT04671069, NCT04671056
- Jun 18, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04951219 · 810 enrolled · United States, Puerto Rico
- Aug 11, 2022Phase 3 study in Liver CirrhosisMadrigal Pharmaceuticals · NCT05500222 · 845 enrolled · United States, Belgium, Canada and more
- Apr 30, 2024Phase 1 study in Renal InsufficiencyMadrigal Pharmaceuticals · NCT06397872 · 28 enrolled · United States
- Oct 8, 2025Sagimet Biosciences’ first study: phase 1 study in HealthyNew to Sagimet BiosciencesSagimet Biosciences · NCT07216313 · 40 enrolled · United States
- Nov 18, 2025Nabiqasim Industries (Pvt)’s first study: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT07249788 · 165 planned · Pakistan
- Jan 7, 2026Phase 2 study in FibrosisMadrigal Pharmaceuticals · NCT07335601 · 120 planned · United States, Canada
- Aug 10, 2026Phase 2 study in Liver DiseasesMadrigal Pharmaceuticals · NCT07763015 · 61 planned · United States
- Aug 25, 2026Phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07848191 · 150 planned · United States
- Aug 25, 2026Phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07830758 · 90 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Liver CirrhosisMadrigal Pharmaceuticals · NCT05500222
- Mar 2027Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04951219
- Nov 2027Primary completion: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07848191
- Nov 2027Primary completion: phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07830758
TargetBeta
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule
Other programs on THRB
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07848191MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 4 | Recruiting | Madrigal Pharmaceuticals | Nov 2027 | 150 |
| NCT07830758MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 1 | Recruiting | Madrigal Pharmaceuticals | Nov 2027 | 90 |
| NCT07763015Liver Diseases · United States | 2 | Recruiting | Madrigal Pharmaceuticals | Jul 2029 | 61 |
| NCT07335601Fibrosis · United States, Canada | 2 | Recruiting | Madrigal Pharmaceuticals | Aug 2028 | 120 |
| NCT07249788MASH - Metabolic Dysfunction-Associated Steatohepatitis · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Oct 16, 2026 | 165 |
| NCT07216313Healthy · United States | 1 | Completed | Sagimet Biosciences | Oct 20, 2025 | 40 |
| NCT06397872Renal Insufficiency · United States | 1 | Completed | Madrigal Pharmaceuticals | Sep 16, 2024 | 28 |
| NCT05500222Liver Cirrhosis · United States, Belgium, Canada and more | 3 | Active, not recruiting | Madrigal Pharmaceuticals | Dec 2026 | 845 |
| NCT04951219Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 3 | Active, not recruiting | Madrigal Pharmaceuticals | Mar 2027 | 810 |
| NCT04671069Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Aug 30, 2019 | 20 |
| NCT04671056Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Dec 11, 2018 | 16 |
| NCT04643795Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Madrigal Pharmaceuticals | Aug 4, 2021 | 87 |
| NCT04197479Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 3 | Completed | Madrigal Pharmaceuticals | Jan 6, 2023 | 1,343 |
| NCT03900429Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more | 3 | Active, not recruiting | Madrigal Pharmaceuticals | Jan 2028 | 1,759 |
| NCT03413124Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Feb 17, 2018 | 16 |
| NCT03220165Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Sep 3, 2017 | 8 |
| NCT03038022Heterozygous Familial Hypercholesterolemia · Denmark, Netherlands, Norway | 2 | Completed | Madrigal Pharmaceuticals | Jan 15, 2018 | 116 |
| NCT02912260Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Madrigal Pharmaceuticals | Oct 25, 2017 | 125 |
| NCT02749578Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | May 2016 | 14 |
| NCT02542969Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Oct 2015 | 25 |
| NCT01519531Drug Safety · United States | 1 | Completed | Madrigal Pharmaceuticals | Nov 2012 | 48 |
| NCT01367873Drug Safety · United States | 1 | Completed | Madrigal Pharmaceuticals | Oct 2011 | 72 |
How it is read
Names in the registry
- “Resmetirom”, 9 entries
- “MGL-3196”, 8 entries
- “VIA-3196”, 2 entries
- “Rezdiffra”, 1 entry
- “MGL-3196 (resmetirom)”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Fatty Liver, 3 studies
- Liver Diseases, 1 study
- Fibrosis, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.